Sarepta (SRPT) Sees Modest Selling Amid $225M Stock Offering
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Sarepta Therapeutics (NASDAQ: SRPT) is down just 0.7% on plans to offer $225 million in common stock. The stock has more than doubled this week after announcing FDA approval.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta's (SRPT) Exondys 51 covered by Humana (HUM) with prior authorization - Bloomberg
- ReWalk Robotics (RWLK) Plans Offering of Ordinary Shares and Warrants
- Stocks with Implied Volatility Movement
Create E-mail Alert Related CategoriesEquity Offerings, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!